Using Belantamab Mafodotin and Pomalidomide in the Treatment of Relapsed/Refractory Multiple Myeloma

Pharmacy Times^® interviewed Suzanne Trudel, MD, MSC, FRCPC, an associate professor at the University of Toronto and a consultant in the Division of Medical Oncology and Hematology at the Princess Margaret Cancer Centre in Toronto, on one of her presentations at the 62^nd ASH Annual Meeting and Exposition. The presentation is on the part 1 results of a dose finding study of belantamab mafodotin (belamaf) in combination with pomalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma.

In this video, Trudel discusses what belamaf and pomalidomide are, and how they work together to treat relapsed/refractory multiple myeloma.